Tyrosine kinase 3D structures
From Proteopedia
(Difference between revisions)
Line 418: | Line 418: | ||
*'''RECEPTOR TYROSINE KINASES - RTK''' | *'''RECEPTOR TYROSINE KINASES - RTK''' | ||
+ | |||
+ | *'''Bone marrow tyrosine kinase'''; Domains – kinase 411-675 | ||
+ | |||
+ | **[[2ekx]] - hTK Bmx SH2 domain – NMR<BR /> | ||
+ | **[[2ys2]] - hTK Bmx Btk motif – NMR<BR /> | ||
+ | |||
+ | *Bone marrow tyrosine kinase complex | ||
+ | |||
+ | **[[3sxr]] - hTK Bmx kinase domain (mutant) + anti-cancer drug<br /> | ||
+ | **[[3sxs]], [[6i99]] - hTK Bmx kinase domain (mutant) + inhibitor<br /> | ||
*'''Bruton’s tyrosine kinase Btk''' (Domains: PH 1-170; SH3 216-273; SH2 273-378; kinase 378-659) | *'''Bruton’s tyrosine kinase Btk''' (Domains: PH 1-170; SH3 216-273; SH2 273-378; kinase 378-659) | ||
Line 444: | Line 454: | ||
**[[4y94]] - bTK Btk kinase domain + inhibitor<br /> | **[[4y94]] - bTK Btk kinase domain + inhibitor<br /> | ||
**[[6mny]] - mTK Btk kinase domain + inhibitor<br /> | **[[6mny]] - mTK Btk kinase domain + inhibitor<br /> | ||
+ | |||
+ | *'''Cbl-c tyrosine kinase''' or '''signal transduction protein Cbl-c''' | ||
+ | |||
+ | **[[3vrn]] - hTK Cbl-c kinase domain <br /> | ||
+ | **[[3vrq]] - hTK Cbl-c kinase domain (mutant)<br /> | ||
+ | **[[3vro]] - hTK Cbl-c kinase domain + Src peptide<br /> | ||
+ | **[[3vrp]] - hTK Cbl-c kinase domain + EGRF peptide<br /> | ||
+ | **[[3vrr]] - hTK Cbl-c kinase domain (mutant) + EGRF peptide<br /> | ||
+ | **[[3op0]] - hTK Cbl-c N-terminal domain (mutant) + EGRF peptide<br /> | ||
*'''c-FMS tyrosine kinase or macrophage colony-stimulating factor 1 receptor''' see [[Colony-stimulating factor receptor]] | *'''c-FMS tyrosine kinase or macrophage colony-stimulating factor 1 receptor''' see [[Colony-stimulating factor receptor]] | ||
*'''DDR1 and DDR2 tyrosine kinase receptors''' see [[Epithelial discoidin domain-containing receptor]] | *'''DDR1 and DDR2 tyrosine kinase receptors''' see [[Epithelial discoidin domain-containing receptor]] | ||
+ | |||
+ | *'''ErbB tyrosine kinase''' see [[Epidermal Growth Factor Receptor]] | ||
+ | |||
+ | *'''Flt3 tyrosine kinase'''; Domains - kinase 564-958 | ||
+ | |||
+ | **[[1rjb]] - hTK Flt3 kinase domain <br /> | ||
+ | **[[4rt7]], [[6il3]], [[5x02]] - hTK Flt3 kinase domain + inhibitor<br /> | ||
+ | **[[4xuf]], [[6jqr]] - hTK Flt3 kinase domain (mutant) + leukemia drug<br /> | ||
+ | **[[3qs9]], [[3qs7]] - hTK Flt3 residues 27-540 + SL cytokine <br /> | ||
*'''Kit tyrosine kinase''' or '''mast/stem cell growth factor receptor Kit'''; Domains – extracellular 1-519; kinase 547-693, 754-935 | *'''Kit tyrosine kinase''' or '''mast/stem cell growth factor receptor Kit'''; Domains – extracellular 1-519; kinase 547-693, 754-935 | ||
Line 460: | Line 488: | ||
**[[2o26]] - hTK Kit residues 25-314 + Kit ligand<br /> | **[[2o26]] - hTK Kit residues 25-314 + Kit ligand<br /> | ||
**[[4k94]], [[4k9e]] - hTK Kit residues 308-518 + antibody<br /> | **[[4k94]], [[4k9e]] - hTK Kit residues 308-518 + antibody<br /> | ||
+ | |||
+ | *'''Matk tyrosine kinase''' or '''megakaryocyte-associated tyrosine-protein kinase''' | ||
+ | |||
+ | **[[3us4]] - hTK Matk SH2 domain <br /> | ||
*'''Mer tyrosine kinase (Domains: FN3 373-483; kinase 570-864)''' | *'''Mer tyrosine kinase (Domains: FN3 373-483; kinase 570-864)''' | ||
Line 476: | Line 508: | ||
**[[7aay]] - hTK Mer kinase domain (mutant) + anti-cancer drug<br /> | **[[7aay]] - hTK Mer kinase domain (mutant) + anti-cancer drug<br /> | ||
- | *''' | + | *'''c-Met tyrosine kinase''' see [[Hepatocyte growth factor receptor]] |
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
*'''MuSK tyrosine kinase''' or '''muscle skeleton receptor tyrosine kinase''' | *'''MuSK tyrosine kinase''' or '''muscle skeleton receptor tyrosine kinase''' | ||
Line 492: | Line 514: | ||
**[[3hkl]] - rTK MuSK Fz-Crd domain <br /> | **[[3hkl]] - rTK MuSK Fz-Crd domain <br /> | ||
**[[1luf]], [[2iep]] - rTK MuSK cytoplasmic domain <br /> | **[[1luf]], [[2iep]] - rTK MuSK cytoplasmic domain <br /> | ||
- | |||
- | *'''Sgk223 tyrosine kinase or sugen kinase''' | ||
- | |||
- | **[[5ve6]] - hTK <br /> | ||
- | |||
- | *'''Matk tyrosine kinase''' or '''megakaryocyte-associated tyrosine-protein kinase''' | ||
- | |||
- | **[[3us4]] - hTK Matk SH2 domain <br /> | ||
- | |||
- | *'''Cbl-c tyrosine kinase''' or '''signal transduction protein Cbl-c''' | ||
- | |||
- | **[[3vrn]] - hTK Cbl-c kinase domain <br /> | ||
- | **[[3vrq]] - hTK Cbl-c kinase domain (mutant)<br /> | ||
- | **[[3vro]] - hTK Cbl-c kinase domain + Src peptide<br /> | ||
- | **[[3vrp]] - hTK Cbl-c kinase domain + EGRF peptide<br /> | ||
- | **[[3vrr]] - hTK Cbl-c kinase domain (mutant) + EGRF peptide<br /> | ||
- | **[[3op0]] - hTK Cbl-c N-terminal domain (mutant) + EGRF peptide<br /> | ||
- | |||
- | *'''Flt3 tyrosine kinase'''; Domains - kinase 564-958 | ||
- | |||
- | **[[1rjb]] - hTK Flt3 kinase domain <br /> | ||
- | **[[4rt7]], [[6il3]], [[5x02]] - hTK Flt3 kinase domain + inhibitor<br /> | ||
- | **[[4xuf]], [[6jqr]] - hTK Flt3 kinase domain (mutant) + leukemia drug<br /> | ||
- | **[[3qs9]], [[3qs7]] - hTK Flt3 residues 27-540 + SL cytokine <br /> | ||
- | |||
- | *'''Tie2 tyrosine kinase''' | ||
- | |||
- | **[[1fvr]] - hTK Tie2 kinase domain <br /> | ||
*'''Ret tyrosine kinase''' or '''proto-oncogene tyrosine protein kinase receptor Ret''' | *'''Ret tyrosine kinase''' or '''proto-oncogene tyrosine protein kinase receptor Ret''' | ||
Line 546: | Line 540: | ||
**[[6osv]], [[6osh]] - hTK ROR2 Kringle domain + antibody<br /> | **[[6osv]], [[6osh]] - hTK ROR2 Kringle domain + antibody<br /> | ||
- | *''' | + | *'''Sgk223 tyrosine kinase or sugen kinase''' |
+ | |||
+ | **[[5ve6]] - hTK <br /> | ||
+ | |||
+ | *'''Tie2 tyrosine kinase''' | ||
+ | |||
+ | **[[1fvr]] - hTK Tie2 kinase domain <br /> | ||
}} | }} | ||
[[Category:Topic Page]] | [[Category:Topic Page]] |
Revision as of 09:04, 30 December 2020
3D structures of tyrosine kinase
Updated on 30-December-2020 - For a general description of the protein see Tyrosine kinase